J9297 Injection pemetrexed (sandoz) 10mg
Also known as: pemetrexed Sandoz, pemetrexed generic
Injection of pemetrexed from Sandoz manufacturer, 10 milligram. Generic multi-targeted antifolate for lung cancer and mesothelioma.
In Plain Language
lung cancer injection; mesothelioma treatment
Clinical Context
Pemetrexed alternative formulation for nonsquamous non-small cell lung cancer and malignant pleural mesothelioma treatment.
RVU Information
CPT J9297 does not have a physician work RVU assigned by CMS. This is typical for supply, drug, and equipment codes — reimbursement is based on Average Sales Price (ASP), fee schedules, or payer contracts rather than the RVU system.
Billing & Documentation
J-codes represent drugs administered by a healthcare provider (not self-administered). Documentation must include the drug name, dosage, route of administration, and medical necessity. Most payers require the National Drug Code (NDC) on the claim. Bill the appropriate administration code (96365-96379) in addition to the drug code.
Specialties
Frequently Asked Questions
What is CPT code J9297?
CPT J9297 (Injection pemetrexed (sandoz) 10mg) is a J Codes (Drugs) code. Injection of pemetrexed from Sandoz manufacturer, 10 milligram. Generic multi-targeted antifolate for lung cancer and mesothelioma.
How is J9297 administered?
CPT J9297 is administered by a healthcare provider, typically via injection or infusion. Pemetrexed alternative formulation for nonsquamous non-small cell lung cancer and malignant pleural mesothelioma treatment. It is used by Oncology, Pulmonology, Surgery.
When is CPT J9297 used?
Pemetrexed alternative formulation for nonsquamous non-small cell lung cancer and malignant pleural mesothelioma treatment.
Track This Code in RVU Edge
Log procedures, calculate wRVUs, and benchmark against MGMA data — all in one app.
CPT® is a registered trademark of the American Medical Association. Data sourced from CMS Physician Fee Schedule RVU26A. Descriptions, synonyms, and clinical context are original content by RVU Edge.